Literature DB >> 27060171

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

Evaren E Page1, Johanna A Kremer Hovinga2, Deirdra R Terrell3, Sara K Vesely3, James N George1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27060171     DOI： 10.1182/blood-2016-03-703827

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  33 in total

1.  Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Pranay Sinha; Jeanne E Hendrickson; Christopher Tormey; Pavan K Bendapudi; Alfred Ian Lee
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

Review 2.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 4.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

Review 5.  Sjögren's syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review.

Authors:  Xiaohan Xu; Tienan Zhu; Di Wu; Lu Zhang
Journal:  Clin Rheumatol       Date:  2017-11-13       Impact factor: 2.980

6.  Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Peter J Kourlas; Shangbin Yang; Susan Geyer; Leslie Witkoff; Haiwa Wu; Camila Masias; James N George; Haifeng M Wu
Journal:  Blood Adv       Date:  2017-10-23

7.  Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood Adv       Date:  2017-04-06

8.  Thrombotic thrombocytopenic purpura masquerading as a stroke in a young man.

Authors:  Christopher James Doig; Louis Girard; Deirdre Jenkins
Journal:  CMAJ       Date:  2019-11-25       Impact factor: 8.262

9.  [Clinical analysis of 61 patients with thrombotic thrombocytopenic purpura].

Authors:  M J Shi; W B Gao; W F Huang; J H Zhu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-09-30

10.  A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.

Authors:  Paul Coppo; Michael Bubenheim; Elie Azoulay; Lionel Galicier; Sandrine Malot; Naïke Bigé; Pascale Poullin; François Provôt; Nihal Martis; Claire Presne; Olivier Moranne; Ruben Benainous; Antoine Dossier; Amélie Seguin; Miguel Hié; Alain Wynckel; Yahsou Delmas; Jean-François Augusto; Pierre Perez; Virginie Rieu; Christelle Barbet; François Lhote; Marc Ulrich; Anne Charvet Rumpler; Sten de Witte; Thierry Krummel; Agnès Veyradier; Ygal Benhamou
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.